Picture courtesy PTI
New Delhi: Bharat Biotech on Friday received approval from the Drugs Controller General of India (DCGI) to conduct its intranasal COVID-19 booster dose trials in India.
The trials are likely to be conducted at nine locations across the country, on 900 individuals.
The Subject Expert Committee (SEC) had earlier given in-principle approval for phase III booster dose study of Bharat Biotech’s intranasal COVID vaccine.
The Hyderabad-based pharmaceutical firm had proposed an intranasal booster dose for those who have been administered two doses of Covaxin or Covishield.
Prime Minister Narendra Modi had said last month that India will soon have an indigenous nasal COVID vaccine.
India launched a ‘precautionary’ third dose for frontline workers and senior citizens earlier this month.
Also Read: Intranasal COVID-19 Vaccine More Effective Than Traditional Counterparts
Berhampur: A stone weighing 2 kg fell from the ‘Singhadwara Gumuta’ of the Lord Jagannath…
New Delhi: Recent pictures of Space Station Commander Sunita Williams from the International Space Station…
Mumbai: Actress Rupali Ganguly recently filed a Rs 50 crore defamation case against her stepdaughter…
Chennai: Odisha will face Manipur in the semifinals of the 14th Hockey India Senior Men’s…
New Delhi: India will again ask Canada for the extradition of designated Khalistani terrorist Arshdeep Singh…
Berhampur: Police have arrested a man from West Bengal for allegedly claiming himself to be…
Mumbai: Carving a niche for himself in Bollywood was not a cakewalk for ‘The Family…
Mumbai: Mukesh Khanna’s Indian superhero series ‘Shaktimaan’ has been making headlines for quite some time…